Clinical trials: Prostate Cancer Patients Treated by Radiotherapy
Prostate Cancer Patients Treated by Radiotherapy
A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy
The primary goal of this study is to assess the impact of an app that reminds patients treated with hypofractionated radiotherapy (HF-RT) for prostate cancer to drink water prior to each radiotherapy session on the number of…
- Trial name
- REFILLPAC-HYPO (NCT06784115)
- Testing
- Reminder App
- Where
- 4 sites in Denmark, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- University Hospital Schleswig-Holstein
Prostate Cancer, Adenocarcinoma of the Prostate
MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
This is a prospective clinical trial examining the use of MRI to measure internal organ motion and any resulting changes in the target volume (shape and location) during a course of post-operative radiation therapy for prostate…
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT01028885
- Testing
- radiation therapy treatment planning/simulation, intensity-modulated radiation therapy, image-guided radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01079793
- Testing
- ixabepilone, adjuvant therapy, intensity-modulated radiation therapy
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Prostate Cancer
PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at…
- Trial name
- NCT04086966
- Testing
- [68Ga]PSMA-PET/MRI or PET/CT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Alabama at Birmingham
Prostate Adenocarcinoma
SURPASS: Stereotactic Ultra-hypofractionated Radiotherapy for Post-prostatectomy Patients: Adaptive Salvage SBRT
The purpose of the study is to evaluate the safety and feasibility of daily-adaptive post-prostatectomy stereotactic body radiotherapy (SBRT) to the prostate fossa in men undergoing salvage radiotherapy after radical…
- Trial name
- NCT07888283
- Testing
- Adaptive stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients
This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.
- Trial name
- NCT03180398
- Testing
- Multiparametric MRI
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Prostate Cancer
Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00032006
- Testing
- brachytherapy, radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Kidney Cancer
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases. PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma
- Trial name
- NCT00769990
- Testing
- genistein, radiation therapy
- Sponsor
- Masonic Cancer Center, University of Minnesota
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Prostate Cancer
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00767286
- Testing
- flutamide, goserelin acetate, low-LET cobalt-60 gamma ray therapy
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00943956
- Testing
- bicalutamide, everolimus, leuprolide acetate
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent).
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03371719
- Testing
- Apalutamide, External Beam Radiation Therapy
- Where
- 360 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- NRG Oncology
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period…
- Trial name
- NCT00331773
- Testing
- Conventional 3D-CRT or IMRT, Hypofractionated 3D-CRT or IMRT
- Where
- 296 sites in United States, Canada
- Volunteers
- 1,116 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
This is a pilot study assessing the role of the general practitioner in performing follow-up reviews on men who have recently completed radical radiotherapy for prostate cancer.
- Trial name
- PROFUGO (NCT00823771)
- Where
- Australia
- Volunteers
- 107 people
- Sponsor
- Barwon Health
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
This phase II trial studies the effect of Sn-117m-DTPA on bone pain in patients with prostate cancer that has spread to the bones. Sn-117m-DTPA is a radioactive therapeutic agent that localizes to bones when given to patients.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT04616547
- Testing
- Questionnaire Administration, Tin Sn 117m Pentetate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy
- Trial name
- PRX32 (NCT03296124)
- Where
- United States
- Sponsor
- University of Florida
Prostatic Neoplasms, Biochemical Recurrence
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
The goal of this clinical trial is to learn if adding metastasis-directed radiotherapy with or without pelvic salvage radiotherapy, to intermittent prostate cancer drugs (intensified hormone therapy) can delay the need to restart…
- Conditions
- Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer
- Trial name
- ESCALATE-RT (NCT07782112)
- Testing
- Radiotherapy for MDT ± WPRT, Androgen Deprivation Therapy (ADT), Enzalutamide
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 140 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Prostate Cancer
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from growing in patients with rising prostate-specific…
- Trial name
- NCT00551525
- Testing
- Radiotherapy, Samarium 153
- Where
- 29 sites in United States
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate
Radiation therapy is one of the standard treatments for men with prostate cancer who have detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker) after surgery.
- Trial name
- HypoFX (NCT01868386)
- Testing
- Hypofractionated therapy
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Timothy Showalter, MD